Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
deaths (OS) | 0.84 [0.75, 0.95] | | < 1 | | 0% | 2 studies (2/-) | 99.8 % | some concern | not evaluable | moderate | crucial | - |
deaths (OS) (extension) | 0.82 [0.71, 0.94] | | < 1 | | 0% | 1 study (1/-) | 99.7 % | NA | not evaluable | | important | - |
progression or deaths (PFS) | 0.83 [0.72, 0.96] | | < 1 | | 0% | 2 studies (2/-) | 99.4 % | some concern | not evaluable | moderate | important | - |
CRR | 1.96 [1.21, 3.17] | | > 1 | | 0% | 1 study (1/-) | 99.7 % | NA | not evaluable | | non important | - |
DOR | 0.35 [0.08, 1.50] | | < 1 | | 91% | 2 studies (2/-) | 92.1 % | some concern | not evaluable | moderate | non important | - |
objective responses (ORR) | 1.10 [0.88, 1.37] | | > 1 | | 0% | 2 studies (2/-) | 79.1 % | some concern | not evaluable | moderate | non important | - |
safety endpoints 00 |
AE (any grade) | 0.81 [0.14, 4.61] | | < 1 | | 71% | 2 studies (2/-) | 59.5 % | some concern | not evaluable | moderate | non important | - |
AE (grade 3-4) | 0.84 [0.68, 1.04] | | < 1 | | 0% | 2 studies (2/-) | 94.5 % | some concern | not evaluable | moderate | non important | - |
AE leading to death (grade 5) | 1.10 [0.70, 1.71] | | < 1 | | 0% | 2 studies (2/-) | 34.1 % | some concern | not evaluable | moderate | non important | - |
AE leading to treatment discontinuation (any grade) | 0.64 [0.23, 1.76] | | < 1 | | 94% | 2 studies (2/-) | 80.8 % | some concern | not evaluable | moderate | non important | - |
SAE (any grade) | 1.01 [0.83, 1.22] | | < 1 | | 3% | 2 studies (2/-) | 47.1 % | some concern | not evaluable | moderate | non important | - |
STRAE (any grade) | 0.87 [0.37, 2.02] | | < 1 | | 93% | 2 studies (2/-) | 62.7 % | some concern | not evaluable | moderate | non important | - |
TRAE (any grade) | 0.52 [0.14, 1.90] | | < 1 | | 91% | 2 studies (2/-) | 83.8 % | some concern | not evaluable | moderate | non important | - |
TRAE (grade 3-4) | 0.58 [0.19, 1.73] | | < 1 | | 96% | 2 studies (2/-) | 83.6 % | some concern | not evaluable | moderate | non important | - |
TRAE leading to death (grade 5) | 0.91 [0.20, 4.07] | | < 1 | | 69% | 2 studies (2/-) | 54.9 % | some concern | not evaluable | moderate | non important | - |
TRAE leading to discontinuation (any grade) | 0.22 [0.12, 0.38] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
Anaemia TRAE (grade 3-4) | 0.70 [0.26, 1.88] | | < 1 | | 78% | 2 studies (2/-) | 76.0 % | some concern | not evaluable | moderate | non important | - |
Asthenia TRAE (grade 3-4) | 0.91 [0.20, 4.21] | | < 1 | | 84% | 2 studies (2/-) | 54.9 % | some concern | not evaluable | moderate | non important | - |
Constipation TRAE (grade 3-4) | 0.02 [0.00, 0.38] | | < 1 | | 0% | 1 study (1/-) | 99.5 % | NA | not evaluable | | non important | - |
Decreased appetite TRAE (grade 3-4) | 2.59 [0.27, 25.03] | | < 1 | | 0% | 1 study (1/-) | 20.7 % | NA | not evaluable | | non important | - |
Fatigue TRAE (grade 3-4) | 0.92 [0.13, 6.29] | | < 1 | | 83% | 2 studies (2/-) | 53.4 % | some concern | not evaluable | moderate | non important | - |
Febrile neutropenia TRAE (grade 3-4) | 0.04 [0.00, 0.27] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | non important | - |
Nausea TRAE (grade 3-4) | 1.73 [0.31, 9.49] | | < 1 | | 0% | 1 study (1/-) | 26.5 % | NA | not evaluable | | non important | - |
Neutropenia TRAE (grade 3-4) | 0.28 [0.01, 14.75] | | < 1 | | 96% | 2 studies (2/-) | 73.1 % | some concern | not evaluable | moderate | non important | - |
Peripheral neuropathy TRAE (grade 3-4) | 0.12 [0.01, 0.95] | | < 1 | | 0% | 1 study (1/-) | 97.7 % | NA | not evaluable | | non important | - |
Pruritus TRAE (grade 3-4) | 1.72 [0.06, 51.51] | | < 1 | | 0% | 1 study (1/-) | 37.9 % | NA | not evaluable | | non important | - |
Rash TRAE (grade 3-4) | 0.86 [0.02, 43.49] | | < 1 | | 0% | 1 study (1/-) | 52.9 % | NA | not evaluable | | non important | - |
Thrombocytopenia TRAE (grade 3-4) | 1.11 [0.55, 2.26] | | < 1 | | 0% | 1 study (1/-) | 38.6 % | NA | not evaluable | | non important | - |
AE (grade 3-4) endpoints 00 |
Anaemia AE (grade 3-4) | 1.08 [0.82, 1.42] | | < 1 | | 0% | 1 study (1/-) | 29.8 % | NA | not evaluable | | non important | - |
Asthenia AE (grade 3-4) | 1.43 [0.81, 2.50] | | < 1 | | 0% | 1 study (1/-) | 10.8 % | NA | not evaluable | | non important | - |
Fatigue AE (grade 3-4) | 0.66 [0.37, 1.17] | | < 1 | | 0% | 1 study (1/-) | 92.1 % | NA | not evaluable | | non important | - |
Febrile neutropenia AE (grade 3-4) | 1.76 [0.81, 3.80] | | < 1 | | 0% | 1 study (1/-) | 7.7 % | NA | not evaluable | | non important | - |
Hypertension AE (grade 3-4) | 2.22 [1.05, 4.68] | | < 1 | | 0% | 1 study (1/-) | 1.8 % | NA | not evaluable | | non important | - |
Leucopenia AE (grade 3-4) | 0.74 [0.44, 1.24] | | < 1 | | 0% | 1 study (1/-) | 87.3 % | NA | not evaluable | | non important | - |
Nausea AE (grade 3-4) | 0.54 [0.23, 1.27] | | < 1 | | 0% | 1 study (1/-) | 92.0 % | NA | not evaluable | | non important | - |
Neutropenia AE (grade 3-4) | 1.38 [1.03, 1.84] | | < 1 | | 0% | 1 study (1/-) | 1.5 % | NA | not evaluable | | non important | - |
Thrombocytopenia AE (grade 3-4) | 1.25 [0.89, 1.76] | | < 1 | | 0% | 1 study (1/-) | 10.1 % | NA | not evaluable | | non important | - |
Vomiting AE (grade 3-4) | 0.86 [0.37, 2.00] | | < 1 | | 0% | 1 study (1/-) | 63.9 % | NA | not evaluable | | non important | - |